Author Archives: William Looney

Health Reform Hazards: Steering Your Course Through the Rhetorical Shallows

By William Looney | Published: December 9, 2009
Image by Getty Images via Dayli Crafting consensus legislation on health reform depends heavily on all parties understanding precisely the terms of the debate. With the two House and Senate bills now topping out at more than 4,000 text pages, prospects for even a basic awareness of the implications of this reform for big pharma and [...]
Posted in FDA, News | Tagged , , , , , , , | Leave a comment

The Case for Specialty Medicines: Is Industry Credible, or Culpable?

By William Looney | Published: November 11, 2009
What’s so special about specialty? This was the question lurking below the surface in many of the presentations at a conference hosted by Pharm Exec’s sister organization, CBI, in Philadelphia last week. Now that the blockbuster era is fading under a wave of patent expirations, big pharma is pinning its hopes on the specialty category [...]
Posted in Strategy | Tagged , , , , , , , | Leave a comment